Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors

Panobinostat, a pan-deacetylase inhibitor, synergistically elicits cytotoxic activity against myeloma (MM) cells in combination with the proteasome inhibitor bortezomib. Because precise mechanisms for panobinostat's anti-MM action still remain elusive, we aimed to clarify the mechanisms of anti...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Bat-Erdene, Ariunzaya, Miki, Hirokazu, Oda, Asuko, Nakamura, Shingen, Teramachi, Jumpei, Amachi, Ryota, Tenshin, Hirofumi, Hiasa, Masahiro, Iwasa, Masami, Harada, Takeshi, Fujii, Shiro, Sogabe, Kimiko, Kagawa, Kumiko, Yoshida, Sumiko, Endo, Itsuro, Aihara, Kenichi, Abe, Masahiro
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2016
נושאים:
Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346698/
https://ncbi.nlm.nih.gov/pubmed/27738323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12594
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים